Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
Marwa N. Rahimi, Jo-Anne Pinson, Joseph Hilton-Proctor, Jessica Van Zuylekom, Benjamin Blyth, Peter D. Roselt, Mohammad B. Haskali
TL;DR
This paper corrects a previously published study on gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting.
Contribution
The contribution is the correction of errors in the original study's data or methodology.
Findings
The correction addresses inaccuracies in the original publication.
It ensures the reliability and accuracy of the reported therapeutic efficacy.
Abstract
Correction for ‘Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting’ by Marwa N. Rahimi et al., RSC Adv., 2026, 16, 2123–2132, https://doi.org/10.1039/D5RA08789A.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNeuropeptides and Animal Physiology · Lung Cancer Research Studies · Advanced Drug Delivery Systems